Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Breast Cancer

  Free Subscription


1 AJR Am J Roentgenol
1 Ann Surg
12 Ann Surg Oncol
2 BMC Cancer
1 Br J Cancer
1 Breast Cancer
1 Breast Cancer Res
15 Breast Cancer Res Treat
2 Cancer
1 Clin Breast Cancer
1 Clin Cancer Res
1 Clin Exp Metastasis
1 Eur Radiol
1 Genes Chromosomes Cancer
1 Int J Radiat Oncol Biol Phys
1 J Clin Oncol
2 J Natl Cancer Inst
6 Lancet
1 Mol Ther Oncol
1 Oncogene
1 Pathology
1 PLoS Genet
5 PLoS One
3 Proc Natl Acad Sci U S A
1 Radiol Artif Intell

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    AJR Am J Roentgenol

  1. WONG JB
    New USPSTF Breast Cancer Screening Recommendations: A Talk With Task Force Vice Chair Dr John Wong.
    AJR Am J Roentgenol. 2024 May 7. doi: 10.2214/AJR.24.31404.
    PubMed         Abstract available

    Ann Surg

  2. LOEHRER AP, Weiss JE, Chatoorgoon KK, Bello OT, et al
    Residential Redlining, Neighborhood Trajectory, and Equity of Breast and Colorectal Cancer Care.
    Ann Surg. 2023 Nov 20. doi: 10.1097/SLA.0000000000006156.
    PubMed         Abstract available

    Ann Surg Oncol

  3. KIM Y, Ganduglia-Cazaban C, Tamirisa N, Lucci A, et al
    Contemporary Analysis of Reexcision and Conversion to Mastectomy Rates and Associated Healthcare Costs for Women Undergoing Breast-Conserving Surgery.
    Ann Surg Oncol. 2024;31:3649-3660.
    PubMed         Abstract available

  4. NGUYEN CL, Cui R, Zhou M, Ali F, et al
    ASO Visual Abstract: Cost-Effectiveness of Radar Localization Versus Wire Localization for Wide Local Excision of Non-palpable Breast Cancer.
    Ann Surg Oncol. 2024 May 9. doi: 10.1245/s10434-024-15383.

  5. LEE EG, Lee DE, Jung SY, Han JH, et al
    Clinical Application of Multimodal Sentinel Lymph Node Mapping Method in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy: An Interim Analysis.
    Ann Surg Oncol. 2024 May 8. doi: 10.1245/s10434-024-15317.
    PubMed         Abstract available

  6. HAMID SA, Schultz KS, Greenup RA
    ASO Author Reflections: "Peace of Mind" After Surgery for Breast Cancer: Implications for Preference-Sensitive Shared Decision Making.
    Ann Surg Oncol. 2024 May 7. doi: 10.1245/s10434-024-15408.

  7. PFOB A, Kokh DB, Surovtsova I, Riedel F, et al
    Oncologic Outcomes for Different Axillary Staging Techniques in Patients with Nodal-Positive Breast Cancer Undergoing Neoadjuvant Systematic Treatment: A Cancer Registry Study.
    Ann Surg Oncol. 2024 May 6. doi: 10.1245/s10434-024-15292.
    PubMed         Abstract available

  8. NIJVELDT JJ, Rajan KK, Boersma K, Noorda EM, et al
    ASO Visual Abstract: Implementation of the Targeted Axillary Dissection Procedure in Clinically Node-Positive Breast Cancer-A Retrospective Analysis.
    Ann Surg Oncol. 2024 May 6. doi: 10.1245/s10434-024-15375.

  9. MUNCK F, Jensen MB, Vejborg I, Gerlach MK, et al
    Residual Axillary Metastases in Node-Positive Breast Cancer Patients After Neoadjuvant Treatment: A Register-Based Study.
    Ann Surg Oncol. 2024 May 4. doi: 10.1245/s10434-024-15354.
    PubMed         Abstract available

  10. CHAUHAN H, Ashrafian H, Takats Z, Leff DR, et al
    ASO Author Reflections: The Impact of DCIS on Positive Margin Rates.
    Ann Surg Oncol. 2024;31:3948-3949.

  11. CHAUHAN H, Jiwa N, Nagarajan VR, Thiruchelvam P, et al
    Clinicopathological Predictors of Positive Resection Margins in Breast-Conserving Surgery.
    Ann Surg Oncol. 2024;31:3939-3947.
    PubMed         Abstract available

  12. CARROLL MC, Yen RW, Leech M, Barth RJ Jr, et al
    A Systematic Review and Meta-analysis of the Role of Preoperative MRI in In-breast Tumor Recurrence After Breast-Conserving Surgery.
    Ann Surg Oncol. 2024;31:3926-3938.
    PubMed         Abstract available

  13. VINGAN PS, Serafin J, Boe L, Zhang KK, et al
    Reducing Disparities: Regional Anesthesia Blocks for Mastectomy with Reconstruction Within Standardized Regional Anesthesia Pathways.
    Ann Surg Oncol. 2024;31:3684-3693.
    PubMed         Abstract available

  14. GONZALEZ L, Johnson NC, Jones VC, Taylor L, et al
    An Observational Cohort Study Comparing Positive Margin Rates Using an Electromagnetic Navigational System Versus Wire Localization in Breast Conservation Surgery.
    Ann Surg Oncol. 2024;31:3669-3671.

    BMC Cancer

  15. SBAITY E, Tamim H, El-Hajj Fuleihan G, Abbas J, et al
    Effect of young age (below 40 years) on oncologic outcomes in Lebanese patients with breast cancer: a matched cohort study.
    BMC Cancer. 2024;24:560.
    PubMed         Abstract available

  16. SAHU RK, Tandon S, Singh S, Das BC, et al
    Methyl CpG binding protein MBD2 has a regulatory role on the BRCA1 gene expression and its modulation by resveratrol in ER+, PR+ & triple-negative breast cancer cells.
    BMC Cancer. 2024;24:566.
    PubMed         Abstract available


  17. TANNE JH
    US expert panel says breast cancer screening should begin at 40.
    BMJ. 2024;385:q1020.

    Br J Cancer

  18. LOHFELD L, Sharma M, Bennett D, Gavin A, et al
    Impact of the COVID-19 pandemic on breast cancer patient pathways and outcomes in the United Kingdom and the Republic of Ireland - a scoping review.
    Br J Cancer. 2024 May 4. doi: 10.1038/s41416-024-02703.
    PubMed         Abstract available

    Breast Cancer

  19. BAO YQ, Yu TH, Huang W, Mao QF, et al
    Simultaneous integrated boost intensity-modulated radiotherapy post breast-conserving surgery: clinical efficacy, adverse effects, and cosmetic outcomes in breast cancer patients.
    Breast Cancer. 2024 May 5. doi: 10.1007/s12282-024-01588.
    PubMed         Abstract available

    Breast Cancer Res

  20. OMILIAN AR, Cannioto R, Mendicino L, Stein L, et al
    CD163(+) macrophages in the triple-negative breast tumor microenvironment are associated with improved survival in the Women's Circle of Health Study and the Women's Circle of Health Follow-Up Study.
    Breast Cancer Res. 2024;26:75.
    PubMed         Abstract available

    Breast Cancer Res Treat

  21. NASIF D, Laurito S, Real S, Branham MT, et al
    Exploring the epigenetic profile of ID4 in breast cancer: bioinformatic insights into methylation patterns and chromatin accessibility dynamics.
    Breast Cancer Res Treat. 2024 May 3. doi: 10.1007/s10549-024-07343.
    PubMed         Abstract available

  22. PITTELL H, Calip GS, Pierre A, Ryals CA, et al
    Racialized economic segregation and inequities in treatment initiation and survival among patients with metastatic breast cancer.
    Breast Cancer Res Treat. 2024 May 3. doi: 10.1007/s10549-024-07319.
    PubMed         Abstract available

  23. SANCHEZ-BAYONA R, Lopez de Sa A, Jerez Gilarranz Y, Sanchez de Torre A, et al
    Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2- advanced breast cancer: a real-world evidence cohort.
    Breast Cancer Res Treat. 2024 May 4. doi: 10.1007/s10549-024-07324.
    PubMed         Abstract available

  24. CHIN K, Landen AH, Kovacs A, Warnberg F, et al
    Tumor-infiltrating lymphocytes as a predictor of axillary and primary tumor pathological response after neoadjuvant chemotherapy in patients with breast cancer: a retrospective cohort study.
    Breast Cancer Res Treat. 2024 May 4. doi: 10.1007/s10549-024-07334.
    PubMed         Abstract available

  25. SATHE C, Accordino MK, DeStephano D, Shah M, et al
    Disparities in PI3K/mTOR inhibitor use, toxicities, and outcomes among patients with metastatic breast cancer.
    Breast Cancer Res Treat. 2024 May 4. doi: 10.1007/s10549-024-07337.
    PubMed         Abstract available

  26. KIMURA T, Takami T, Piao Y, Ntalla I, et al
    Treatment patterns and clinical outcomes in patients with metastatic triple-negative breast cancer: a large-scale data analysis using the Japanese claims database.
    Breast Cancer Res Treat. 2024 May 5. doi: 10.1007/s10549-024-07273.
    PubMed         Abstract available

  27. COOMBES RC, Angelou C, Al-Khalili Z, Hart W, et al
    Correction: Performance of a novel spectroscopy-based tool for adjuvant therapy decision-making in hormone receptor-positive breast cancer: a validation study.
    Breast Cancer Res Treat. 2024 May 5. doi: 10.1007/s10549-024-07276.

  28. RICHMAN J, Schuster G, Buus R, Lopez-Knowles E, et al
    Clinical and molecular predictors of very late recurrence in oestrogen receptor-positive breast cancer patients.
    Breast Cancer Res Treat. 2024 May 6. doi: 10.1007/s10549-024-07311.
    PubMed         Abstract available

  29. CHEN Y, Zhang R, Yan Y, Li H, et al
    Effectiveness of gonadotropin-releasing hormone agonists for ovarian function suppression in premenopausal patients with hormone receptor-positive breast cancer: a retrospective single-center real-world study.
    Breast Cancer Res Treat. 2024 May 6. doi: 10.1007/s10549-024-07323.
    PubMed         Abstract available

  30. SAINT K, Nemirovsky D, Lessing A, Chen Y, et al
    Impact of exercise on chemotherapy-induced peripheral neuropathy in survivors with post-treatment primary breast cancer.
    Breast Cancer Res Treat. 2024 May 7. doi: 10.1007/s10549-024-07342.
    PubMed         Abstract available

  31. LIN B, LeVee A, Cao L, Basho R, et al
    Left ventricular global longitudinal strain is worse in BRCA mutation positive breast cancer patients prior to cancer treatment and premature menopause.
    Breast Cancer Res Treat. 2024 May 8. doi: 10.1007/s10549-024-07344.
    PubMed         Abstract available

  32. KLEIN E, Kiechle M, Josipovic A, Anders SI, et al
    Long-term prospective outcome data using EndoPredict as risk stratification and chemotherapy decision biomarker in hormone receptor-positive, HER2-negative early breast cancer.
    Breast Cancer Res Treat. 2024 May 9. doi: 10.1007/s10549-024-07346.
    PubMed         Abstract available

  33. FAIRHURST K, McIntosh SA, Cutress RI, Potter S, et al
    Current axillary management of patients with early breast cancer and low-volume nodal disease undergoing primary surgery: results of a United Kingdom national practice survey.
    Breast Cancer Res Treat. 2024 May 10. doi: 10.1007/s10549-024-07328.
    PubMed         Abstract available

  34. ZHANG S, Yang H, Xu Y, Wang S, et al
    Do we need reshape rTNM staging system for ipsilateral breast tumor recurrence of breast cancer? A population-based, propensity score matched cohort study.
    Breast Cancer Res Treat. 2024 May 10. doi: 10.1007/s10549-024-07340.
    PubMed         Abstract available

  35. WU Y, Tran T, Dwabe S, Sarkissyan M, et al
    Retraction Note: A83-01 inhibits TGF-beta-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells.
    Breast Cancer Res Treat. 2024 May 10. doi: 10.1007/s10549-024-07371.


  36. GUO H, Malone KE, Heckbert SR, Li CI, et al
    Statin use and risks of breast cancer recurrence and mortality.
    Cancer. 2024 May 6. doi: 10.1002/cncr.35362.
    PubMed         Abstract available

  37. HOVHANNISYAN M, Zemankova P, Nehasil P, Matejkova K, et al
    Population-specific validation and comparison of the performance of 77- and 313-variant polygenic risk scores for breast cancer risk prediction.
    Cancer. 2024 May 8. doi: 10.1002/cncr.35337.
    PubMed         Abstract available

    Clin Breast Cancer

  38. VARNIER R, Moskal A, Bodelet C, Peron J, et al
    Implementing Indicators and Trajectories of Return to Work After Breast Cancer Diagnosis: A Mixed-Methods Study Using the French National Healthcare Insurance Database and Stakeholder Consultation.
    Clin Breast Cancer. 2024 Apr 7:S1526-8209(24)00104.
    PubMed         Abstract available

    Clin Cancer Res

  39. BARDIA A, Sun S, Thimmiah N, Coates JT, et al
    Antibody Drug Conjugate Sacituzumab Govitecan Enables A Sequential TOP1/PARP Inhibitor Cancer Therapy Strategy in Breast Cancer Patients.
    Clin Cancer Res. 2024 May 6. doi: 10.1158/1078-0432.CCR-24-0428.
    PubMed         Abstract available

    Clin Exp Metastasis

  40. BAUGH AG, Gonzalez E, Narumi VH, Kreger J, et al
    A new Neu-a syngeneic model of spontaneously metastatic HER2-positive breast cancer.
    Clin Exp Metastasis. 2024 May 8. doi: 10.1007/s10585-024-10289.
    PubMed         Abstract available

    Eur Radiol

  41. FU Y, Lei YT, Huang YH, Mei F, et al
    Longitudinal ultrasound-based AI model predicts axillary lymph node response to neoadjuvant chemotherapy in breast cancer: a multicenter study.
    Eur Radiol. 2024 May 10. doi: 10.1007/s00330-024-10786.
    PubMed         Abstract available

    Genes Chromosomes Cancer

  42. CHANG HY, Dermawan JK, Kuba MG, Crago AM, et al
    Clinicopathologic and molecular correlates to neoadjuvant chemotherapy-induced pathologic response in breast angiosarcoma.
    Genes Chromosomes Cancer. 2024;63:e23240.
    PubMed         Abstract available

    Int J Radiat Oncol Biol Phys

  43. KOLEOSO O, Toumbacaris N, Brogi E, Zhang Z, et al
    The presence of extensive lymphovascular invasion (LVI) is associated with higher risks of local-regional recurrence compared to usual LVI in curatively treated breast cancer patients.
    Int J Radiat Oncol Biol Phys. 2024 May 4:S0360-3016(24)00625.
    PubMed         Abstract available

    J Clin Oncol

  44. RAPP SR, Dressler EV, Brown WM, Wade JL 3rd, et al
    Phase III Randomized, Placebo-Controlled Clinical Trial of Donepezil for Treatment of Cognitive Impairment in Breast Cancer Survivors After Adjuvant Chemotherapy (WF-97116).
    J Clin Oncol. 2024 May 6:JCO2301100. doi: 10.1200/JCO.23.01100.
    PubMed         Abstract available

    J Natl Cancer Inst

  45. VO JB, Ramin C, Veiga LHS, Brandt C, et al
    Long-term cardiovascular disease risk after anthracycline and trastuzumab treatments in U.S. breast cancer survivors.
    J Natl Cancer Inst. 2024 May 8:djae107. doi: 10.1093.
    PubMed         Abstract available

  46. Correction to: Tamoxifen for the Prevention of Breast Cancer: Late Results of the Italian Randomized Tamoxifen Prevention Trial Among Women With Hysterectomy.
    J Natl Cancer Inst. 2024 May 8:djae093. doi: 10.1093.


  47. COLES CE, Haviland JS, Kirby AM, Griffin C, et al
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial - Authors' reply.
    Lancet. 2024;403:1752.

  48. GREGUCCI F, Ciabattoni A
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
    Lancet. 2024;403:1751-1752.

  49. MULLIEZ T, De Ridder M
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
    Lancet. 2024;403:1751.

  50. GUINOT JL, Gutierrez C, Hannoun-Levi JM
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
    Lancet. 2024;403:1750-1751.

  51. MIZUMOTO M, Oshiro Y, Sakurai H
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
    Lancet. 2024;403:1749-1750.

  52. ZHAO D, Li Y, Qu Y, He C, et al
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
    Lancet. 2024;403:1749.

    Mol Ther Oncol

  53. GHARAVI AT, Irian S, Niknejad A, Parang K, et al
    Harnessing exosomes as a platform for drug delivery in breast cancer: A systematic review for in vivo and in vitro studies.
    Mol Ther Oncol. 2024;32:200800.
    PubMed         Abstract available


  54. DAS C, Bhattacharya A, Adhikari S, Mondal A, et al
    A prismatic view of the epigenetic-metabolic regulatory axis in breast cancer therapy resistance.
    Oncogene. 2024 May 8. doi: 10.1038/s41388-024-03054.
    PubMed         Abstract available


  55. LAMI K, Yoon HS, Parwani AV, Pham HHN, et al
    Validation of prostate and breast cancer detection artificial intelligence algorithms for accurate histopathological diagnosis and grading: a retrospective study with a Japanese cohort.
    Pathology. 2024 Apr 19:S0031-3025(24)00101-6. doi: 10.1016/j.pathol.2024.
    PubMed         Abstract available

    PLoS Genet

  56. MAJOCHA MR, Jackson DE, Ha NH, Amin R, et al
    Resf1 is a compound G4 quadruplex-associated tumor suppressor for triple negative breast cancer.
    PLoS Genet. 2024;20:e1011236.
    PubMed         Abstract available

    PLoS One

  57. LEVKOVICH I, Rosman L, Signorelli C
    "Hearing the pupils' voices through my own struggles": A qualitative study of return to work among school counselors who are breast cancer survivors.
    PLoS One. 2024;19:e0300396.
    PubMed         Abstract available

  58. BEHR M, Alizadeh L, Buckner-Baiamonte L, Roberts B, et al
    Structured illumination microscopy for cancer identification in diagnostic breast biopsies.
    PLoS One. 2024;19:e0302600.
    PubMed         Abstract available

  59. VERMEHREN-SCHMAEDICK A, Peto M, Wagoner W, Chiotti KE, et al
    Mutation of SIVA, a candidate metastasis gene identified from clonally related bilateral breast cancers, promotes breast cancer cell spread in vitro and in vivo.
    PLoS One. 2024;19:e0302856.
    PubMed         Abstract available

  60. KAWAZU M, Saso K, Tong KI, McQuire T, et al
    Correction: Histone Demethylase JMJD2B Functions as a Co-Factor of Estrogen Receptor in Breast Cancer Proliferation and Mammary Gland Development.
    PLoS One. 2024;19:e0303780.
    PubMed         Abstract available

  61. SCHWARZ F, Arefian H, Hartmann M, Runnebaum I, et al
    Correction: Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany.
    PLoS One. 2024;19:e0303776.
    PubMed         Abstract available

    Proc Natl Acad Sci U S A

  62. GOYETTE MA, Stevens LE, DePinho CR, Seehawer M, et al
    Cancer-stromal cell interactions in breast cancer brain metastases induce glycocalyx-mediated resistance to HER2-targeting therapies.
    Proc Natl Acad Sci U S A. 2024;121:e2322688121.
    PubMed         Abstract available

  63. ASHOKAN A, Sarkar S, Kamran MZ, Surnar B, et al
    Simultaneous targeting of peripheral and brain tumors with a therapeutic nanoparticle to disrupt metabolic adaptability at both sites.
    Proc Natl Acad Sci U S A. 2024;121:e2318119121.
    PubMed         Abstract available

  64. CHEN J, Liu X, Zou Y, Gong J, et al
    A high-fat diet promotes cancer progression by inducing gut microbiota-mediated leucine production and PMN-MDSC differentiation.
    Proc Natl Acad Sci U S A. 2024;121:e2306776121.
    PubMed         Abstract available

    Radiol Artif Intell

  65. BAHL M, Do S
    Artificial Intelligence for Breast Cancer Screening: Trade-offs between Sensitivity and Specificity.
    Radiol Artif Intell. 2024;6:e240184.

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.